688505.SS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 09:00):

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products...

Stats
Dagens volum	2.95M
Gjennomsnittsvolum	3.20M
Markedsverdi	652.35M
EPS	CNY0 ( 2024-04-29 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	70.27
ATR14	CNY0.0100 (0.13%)

Volum Korrelasjon

Lang: 0.14 (neutral)

Kort: -0.49 (neutral)

Signal:(39.4) Neutral

Shanghai Fudan-Zhangjiang Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Shanghai Fudan-Zhangjiang Korrelasjon - Valuta/Råvare

0.14
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.24
( neutral )

0.18
( neutral )

0.54
( weak )

Shanghai Fudan-Zhangjiang Økonomi

Annual	2023
Omsetning:	CNY845.34M
Bruttogevinst:	CNY735.99M (87.06 %)
EPS:	CNY0.110

FY	2023
Omsetning:	CNY845.34M
Bruttogevinst:	CNY735.99M (87.06 %)
EPS:	CNY0.110

FY	2022
Omsetning:	CNY1.03B
Bruttogevinst:	CNY947.10M (91.85 %)
EPS:	CNY0.130

FY	2021
Omsetning:	CNY1.14B
Bruttogevinst:	CNY1.06B (92.90 %)
EPS:	CNY0.220

Financial Reports:

No articles found.

Shanghai Fudan-Zhangjiang

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.